The estimated Net Worth of Brian J Caveney is at least $10.7 Milion dollars as of 27 March 2024. Brian Caveney owns over 11,556 units of Labcorp stock worth over $7,190,909 and over the last 7 years he sold LH stock worth over $0. In addition, he makes $3,479,820 as Executive Vice President, President oraz Diagnostics and Chief Medical Officer at Labcorp.
Sign up
Brian Caveney LH stock SEC Form 4 insiders trading
Brian has made over 19 trades of the Labcorp stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 11,556 units of LH stock worth $2,522,559 on 27 March 2024.
The largest trade he's ever made was exercising 11,556 units of Labcorp stock on 27 March 2024 worth over $2,522,559. On average, Brian trades about 1,019 units every 49 days since 2017. As of 27 March 2024 he still owns at least 32,942 units of Labcorp stock.
You can see the complete history of Brian Caveney stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Brian Caveney biography
Dr. Brian J. Caveney M.D., J.D. serves as Executive Vice President, President, Diagnostics and Chief Medical Officer of the Company. Prior to that he served as Senior Vice President and Chief Medical Officer from September 2017. In his role as Chief Medical Officer, he has broad responsibility for the medical and scientific strategy of the enterprise. From 2011 until joining the Company, Dr. Caveney was Chief Medical Officer at Blue Cross and Blue Shield of North Carolina (Blue Cross NC). In addition to various roles in the Healthcare Division of the core health plan, Dr. Caveney also served as Chief Clinical Officer of Mosaic Health Solutions, a wholly owned subsidiary of Blue Cross NC for strategic investments in diversified health solutions businesses. Prior to joining Blue Cross NC, Dr. Caveney was a practicing physician and assistant professor at Duke University Medical Center and also provided consulting services for several companies in the Research Triangle Park, North Carolina, region. Dr. Caveney holds an M.D. from the West Virginia University School of Medicine, a J.D. from the West Virginia University College of Law and an M.P.H. in health policy and administration from the University of North Carolina at Chapel Hill. He completed his residency at Duke University Medical Center and is board-certified in preventive medicine, with a specialty in occupational and environmental medicine. He is the past President of the Southeastern Atlantic College of Occupational and Environmental Medicine.
What is the salary of Brian Caveney?
As the Executive Vice President, President oraz Diagnostics and Chief Medical Officer of Labcorp, the total compensation of Brian Caveney at Labcorp is $3,479,820. There are 3 executives at Labcorp getting paid more, with Glenn Eisenberg having the highest compensation of $8,822,760.
How old is Brian Caveney?
Brian Caveney is 46, he's been the Executive Vice President, President oraz Diagnostics and Chief Medical Officer of Labcorp since 2019. There are 24 older and 1 younger executives at Labcorp. The oldest executive at Labcorp Holdings Inc. is Jean-Luc Belingard, 71, who is the Independent Director.
What's Brian Caveney's mailing address?
Brian's mailing address filed with the SEC is 531, South Spring Street, Burlington, Alamance County, North Carolina, 27215, United States.
Insiders trading at Labcorp
Over the last 19 years, insiders at Labcorp have traded over $236,972,149 worth of Labcorp stock and bought 10,666 units worth $1,520,331 . The most active insiders traders include Mahon Thomas P Mac, Garheng Kong oraz David P King. On average, Labcorp executives and independent directors trade stock every 11 days with the average trade being worth of $2,652,442. The most recent stock trade was executed by Der Vaart Sandra D Van on 19 August 2024, trading 2,000 units of LH stock currently worth $454,100.
What does Labcorp do?
recognized for our innovation, quality, and customer convenience, labcorp delivers timely, accurate results for improved patient care. with scientific expertise in esoteric testing, genomics, and clinical and anatomic pathology, labcorp performs more than one million tests on approximately 400,000 samples each day. labcorp is a pioneer in applying advances in medicine and science to laboratory testing, with more than 35 years of experience in serving physicians and their patients. labcorp operates a sophisticated laboratory network, with corporate headquarters in burlington, nc, and more than 34,000 employees worldwide. our more than 220,000 clients include physician offices, hospitals, managed care organizations, and biotechnology and pharmaceutical companies. laboratory corporation of america holdings is listed on the new york stock exchange (nyse) under ticker symbol lh.
What does Labcorp's logo look like?
Complete history of Brian Caveney stock trades at Labcorp
Labcorp executives and stock owners
Labcorp executives and other stock owners filed with the SEC include:
-
Glenn Eisenberg,
Chief Financial Officer, Executive Vice President -
Adam Schechter,
President, Chief Executive Officer, Director -
Adam H. Schechter,
Pres, CEO & Chairman -
Brian Caveney,
Executive Vice President, President, Diagnostics and Chief Medical Officer -
Lance Berberian,
Executive Vice President, Chief Technology Officer, Chief Information Officer -
Mark Schroeder,
Executive Vice President, President of Diagnostics Laboratory Operations and Global Supply Chain -
Glenn A. Eisenberg,
CFO & Exec. VP -
Mark S. Schroeder,
Exec. VP and Pres of Diagnostics Laboratory Operations & Global Supply Chain -
Dr. Paul R. Kirchgraber M.D.,
Exec. VP & CEO of Covance Drug Devel. -
Dr. Brian J. Caveney M.P.H., M.D., J.D., MPH,
Exec. VP, Pres of Diagnostics & Chief Medical Officer -
Peter Neupert,
Lead Independent Director -
Kerrii Anderson,
Independent Director -
Garheng Kong,
Independent Director -
Robert Williams,
Independent Director -
Richelle Parham,
Independent Director -
D. Gary Gilliland,
Independent Director -
Jean-Luc Belingard,
Independent Director -
Jeffrey Davis,
Independent Director -
Clarissa Willett,
Vice President, Investor Relations -
Peter Wilkinson,
Senior Vice President, Chief Accounting Officer -
Paul Kirchgraber,
Executive Vice President and Chief Executive Officer - Covance Drug Development -
Sandra Van Der Vaart,
Executive Vice President, Chief Legal Officer, Chief Compliance Officer and Secretary -
Amy Summy,
Executive Vice President, Chief Marketing Officer -
Judith Seltz,
Chief Human Resource Officer, Executive Vice President -
Chas Cook,
VP of Investor Relations -
Dr. Marcia T. Eisenberg Ph.D.,
Chief Scientific Officer & Sr. VP -
Lance V. Berberian,
Exec. VP and Chief Information & Technology Officer -
Peter J. Wilkinson,
Sr. VP & Chief Accounting Officer -
Dr. Michelle Abelson Ph.D.,
Laboratory Director of Operations -
Anita Z Graham,
EVP, CHRO -
R Sanders Williams,
Director -
Edward T Dodson,
Principal Accounting Officer -
Lisa J Uthgenannt,
Chief Human Resources Officer -
David P King,
Director -
M. Huff Gary,
CEO, LabCorp Diagnostics -
John D Ratliff,
CEO, Covance Drug Development -
F Samuel Iii Eberts,
Chief Legal Officer, Secretary -
Robert E Jr Mittelstaedt,
Director -
Kathryn E Wengel,
Director -
Thomas Pike,
Pres & CEO Clinical Business -
Arthur H Rubenstein,
Director -
M Keith Weikel,
Director -
William B Hayes,
Sr. Vice President -
Wendy E Lane,
Director -
Lidia Fonseca,
Chief Information Officer -
Bradford T Smith,
EVP, Chf Legal Offcr,Secretary -
Don M Hardison,
EVP, COO -
Mahon Thomas P Mac,
CEO and Chairman of the Board -
N Anthony Coles,
Director -
William Haas,
EVP, Sales & Marketing -
Andrew J Conrad,
EVP, Chief Scientific Officer -
Goldman Myla Lai,
EVP & Chief Medical Officer -
Benjamin R Miller,
EVP, Oncology Products & Serv -
Andrew G Wallace,
Director -
Allen W Troub,
EVP, Western Operations -
Woodrow L Cook,
EVP, Eastern Operations -
Richard L Novak,
EVP & Strategic Planning -
Deborah L Keller,
CEO, Covance Drug Development -
James T. Jr. Boyle,
Senior Vice President -
Joseph L Herring,
CEO of Covance Drug Division -
Mark E Brecher,
Chief Medical Officer -
Kirsten Marie Kliphouse,
Director -
Paul Rothman,
Director -
Jonathan P. Di Vincenzo,
EVP, Pres, Central Labs & Intl -
Megan D. Bailey,
EVP, Chief Strategy Officer